Aficamten · Myqorzo

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Hypertrophic Cardiomyopathy

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (3)
UK
  • Symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy in eligible adults
Product first approved 2026biospace.com
EU
  • Symptomatic (NYHA class II-III) obstructive hypertrophic cardiomyopathy in adults
Product first approved 2026finviz.com
CN
  • Adults with NYHA class II-III obstructive hypertrophic cardiomyopathy, to improve exercise capacity and symptoms
Product first approved 2025biospace.com

Company guidance: regulatory filing expected Q4 2026 (Cytokinetics, 4 Nov 2026). “Following positive results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026.” Source ↗

The company’s own stated timing, shown beside the ClinicalTrials.gov estimate. Neither is a confirmed date.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (5)
Hypertrophic Cardiomyopathy
NCT07023341 · Bayer
2025-06-30 – 2028-05-30 · Obstructive Hypertrophic Cardiomyopathy
What this study did
NCT06081894 · Cytokinetics
2023-08-31 – 2026-11 · Symptomatic Non-Obstructive Hypertrophic Cardiomyopathy
What this study did
NCT06116968 · Corxel Pharmaceuticals
Run by former owner Corxel Pharmaceuticals
2023-11-14 – 2025-10-20 · Obstructive Hypertrophic Cardiomyopathy
What this study did
Phase 2/3 (2)
Hypertrophic Cardiomyopathy
NCT06412666 · Cytokinetics
2024-05-29 – 2030-01 · Pediatric, Symptomatic Obstructive Hypertrophic Cardiomyopathy
What this study did
NCT04848506 · Cytokinetics
2021-05-06 – 2029-03 · Symptomatic Hypertrophic Cardiomyopathy (HCM)
What this study did
Phase 2 (1)
Hypertrophic Cardiomyopathy
NCT04219826 · Cytokinetics
2020-01-10 – 2023-02-28 · Hypertrophic Cardiomyopathy (HCM)
What this study did
Phase 1 (3)
Hypertrophic Cardiomyopathy
NCT03767855 · Cytokinetics
2018-12-04 – 2020-01-03 · Symptomatic Obstructive Hypertrophic Cardiomyopathy, Healthy Subjects
What this study did
Other / comorbidity
NCT05924815 · Cytokinetics
2023-05-15 – 2023-11-14 · Healthy Participants
What this study did
Phase 4 (1)
Hypertrophic Cardiomyopathy
NCT07600177 · Oregon Health and Science University
2026-05-05 – 2027-03-15 · Hypertrophic Cardiomyopathy (HCM)
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Hypertrophic Cardiomyopathy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Aficamten (Myqorzo): this drugApprovedSmall moleculeCardiac myosin (inhibitor)Reliable signal
NCT05767346: Change in Peak Oxygen Uptake (pVO2) by Cardiopulmonary Exercise Testing (CPET) (Baseline to Week 24): Aficamten 1.07 mL/kg/min (Standard Deviation 2.767) | Metoprolol -1.24 mL/kg/min (Standard Deviation 2.186)
NCT05186818: Change From Baseline in pVO2 at Week 24 (Baseline to Week 24): Aficamten up to 20 mg 1.76 mL/kg/min (Standard Error 0.25) | Placebo to Match Aficamten 0.02 mL/kg/min (Standard Error 0.25)
Mavacamten (Camzyos)ApprovedSmall moleculeCardiac myosin (inhibitor)Partial signal
NCT04349072: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 (Week 16): Mavacamten 10 Participants | Placebo to Mavacamten 43 Participants
Propranolol (Inderal LA)ApprovedSmall moleculeBeta-1/beta-2 adrenergic receptorsnot yet gradedNo reviewed efficacy summary in this indication
HRS-1893Phase 3UndisclosedCardiac myosin (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
Sotagliflozin (Inpefa)Phase 3Small moleculeSGLT1/2 (dual)not yet gradedNo reviewed efficacy summary in this indication
Delocamten
Phase 2(overall)
Small moleculeCardiac myosin (inhibitor)
not yet graded(overall)
No reviewed efficacy summary in this indication
Ninerafaxstat (IMB-101)Phase 2Small moleculeCardiac fatty-acid oxidationnot yet gradedNo reviewed efficacy summary in this indication
Ulacamten
Phase 2(overall)
Small moleculeCardiac myosin (inhibitor)
not yet graded(overall)
No reviewed efficacy summary in this indication

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Myqorzo (Aficamten) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 4Hypertrophic CardiomyopathyRecruiting
Est. primary completion 2026-12-31 · NCT07600177 · CT.gov ↗
What to watch
2029 (1)
March 2029 (1)
Phase 2/3Hypertrophic CardiomyopathyEnrolling by invitation
Est. primary completion 2029-03 · NCT04848506 · CT.gov ↗
What to watch
2030 (1)
January 2030 (1)
Phase 2/3Hypertrophic CardiomyopathyActive not recruiting
Est. primary completion 2030-01 · NCT06412666 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(2)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

5 May 2026Topline resultACACIA-HCM Phase 3 of aficamten in non-obstructive HCM met both dual primary endpoints
Cytokinetics · Source ↗
19 December 2025ApprovalFDA Boxed Warning on Myqorzo (NDA219083)
US, FDA · FDA · Source ↗